{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:51:27Z","timestamp":1791409887827,"version":"4.3.3"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007620","name":"Department of Education of Liaoning Province","doi-asserted-by":"publisher","award":["LJ242510140006"],"award-info":[{"award-number":["LJ242510140006"]}],"id":[{"id":"10.13039\/501100007620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007620","name":"Department of Education of Liaoning Province","doi-asserted-by":"publisher","award":["LJ212410140038"],"award-info":[{"award-number":["LJ212410140038"]}],"id":[{"id":"10.13039\/501100007620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007765","name":"Shenyang Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["23-503-6-12"],"award-info":[{"award-number":["23-503-6-12"]}],"id":[{"id":"10.13039\/501100007765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007933","name":"Liaoning University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007933","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110333","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:55:56Z","timestamp":1786463756000},"page":"110333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel 1,3,5-triazine derivatives containing benzo[d]imidazole scaffold as PI3K inhibitors"],"prefix":"10.1016","volume":"181","author":[{"given":"Ju","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhe","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congjun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110333_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116425","article-title":"Design, synthesis, and biological evaluation of novel benzimidazole derivatives as anti-cervical cancer agents through PI3K\/Akt\/mTOR pathway and tubulin inhibition","volume":"271","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110333_bb0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","article-title":"PI3K signalling: the path to discovery and understanding","volume":"13","author":"Vanhaesebroeck","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.110333_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106412","article-title":"1H-indazoles derivatives targeting PI3K\/AKT\/mTOR pathway: synthesis, anti-tumor effect and molecular mechanism","volume":"133","author":"Wang","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110333_bb0020","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.bmcl.2016.01.003","article-title":"Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model","volume":"26","author":"Han","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110333_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106738","article-title":"Structure-based drug design, synthesis, and biological evaluation of novel 1,3,5-triazine or pyrimidine derivatives containing benzoyl hydrazine moiety as PI3K\u03b1 selective inhibitors","volume":"140","author":"Fu","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110333_bb0030","article-title":"Oncogenic activation of PIK3CA in cancers: emerging targeted therapies in precision oncology","volume":"12","author":"Wang","year":"2024","journal-title":"Genes Dis."},{"key":"10.1016\/j.bioorg.2026.110333_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105405","article-title":"Development of anti-breast cancer PI3K inhibitors based on 7-azaindole derivatives through scaffold hopping: design, synthesis and in vitro biological evaluation","volume":"117","author":"Yang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110333_bb0040","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.canlet.2018.07.011","article-title":"Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3K\u03b1-selective inhibitor CYH33 in breast cancer","volume":"433","author":"Liu","year":"2018","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110333_bb0045","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1021\/acs.jmedchem.5c03376","article-title":"Discovery of novel disubstituted l-prolinamide derivatives as selective PI3K\u03b1 inhibitors for anticancer therapy","volume":"69","author":"Wang","year":"2026","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.bioorg.2026.110333_bb0050","doi-asserted-by":"crossref","first-page":"24404","DOI":"10.1021\/acs.jmedchem.5c02352","article-title":"Structure-guided design of a highly selective PI3K\u03b1 inhibitor overcoming metabolic dysregulation with potent anti-breast cancer efficacy","volume":"68","author":"Hou","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110333_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115754","article-title":"Design, synthesis and bioevaluation of PI3K\u03b1-selective inhibitors as potential colorectal cancer drugs","volume":"260","author":"Zheng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2026.110333_bb0060","doi-asserted-by":"crossref","first-page":"15387","DOI":"10.1021\/acs.jmedchem.4c00992","article-title":"Rational design of a novel 6h-benzo[c]chromen series as selective PI3K\u03b1 inhibitors","volume":"67","author":"Shi","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110333_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117671","article-title":"Design, synthesis and biological evaluation of novel 4-(thieno[3,2-d]pyrimidin-4-yl)morpholine derivatives as potent antitumor agents","volume":"293","author":"Liu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110333_bb0070","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jare.2024.03.002","article-title":"Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3K\u03b1 inhibitors","volume":"68","author":"Liu","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.bioorg.2026.110333_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116680","article-title":"1,3,5-triazine as a promising scaffold in the development of therapeutic agents against breast cancer","volume":"276","author":"Lim","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110333_bb0080","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ejmech.2017.09.035","article-title":"1,3,5-triazines: a promising scaffold for anticancer drugs development","volume":"142","author":"Cascioferro","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110333_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108486","article-title":"Design, synthesis, bioactivity, X-ray crystallography, and molecular docking studies of chrysin-1,3,5-triazine derivatives as anticancer agents","volume":"161","author":"Xue","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110333_bb0090","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3390\/ph8040696","article-title":"Controlling persister and biofilm cells of gram-negative bacteria with a new 1,3,5-triazine derivative","volume":"8","author":"Bahar","year":"2015","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110333_bb0095","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jscs.2015.01.004","article-title":"Synthesis, characterization and antimicrobial activity of some novel 4-(4-(arylamino)-6-(piperidin-1-yl)-1,3,5-triazine-2-ylamino)-N-(pyrimidin-2-yl)benzenesulfonamides","volume":"20","author":"Desai","year":"2016","journal-title":"J. Saudi Chem. Soc."},{"key":"10.1016\/j.bioorg.2026.110333_bb0100","article-title":"Design, discovery, molecular docking, dynamics and in-silico ADME-T evaluation of novel hybrids of 1,3,5-triazine-morpholino-thiazine as an anti-diabetic agent in Wistar rats via inhibition of DPP-4","volume":"1332","author":"Gupta","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110333_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140717","article-title":"Evaluation of isatin-1,3,5-triazine-benzylamine hybrids as multi-target directed ligands against Alzheimer\u2019s disease","volume":"1324","author":"Tamaddon-Abibigloo","year":"2025","journal-title":"J. Mol. Struct."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110333_bb0110","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1111\/j.1349-7006.2007.00580.x","article-title":"ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms","volume":"98","author":"Kong","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2026.110333_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106211","article-title":"Based on 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474), design, synthesis and biological evaluation of novel PI3K\u03b1 selective inhibitors","volume":"130","author":"Wang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110333_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106263","article-title":"Novel 6-amino-1,3,5-triazine derivatives as potent BTK inhibitors: structure-activity relationship (SAR) analysis and preliminary mechanism investigation","volume":"130","author":"Xiao","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110333_bb0125","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/cbdd.13986","article-title":"Novel 1,3,5-triazine-nicotinohydrazide derivatives induce cell arrest and apoptosis in osteosarcoma cancer cells and inhibit osteosarcoma in a patient-derived orthotopic xenograft mouse model","volume":"99","author":"Su","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110333_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115453","article-title":"Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2","volume":"28","author":"Kuriwaki","year":"2020","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110333_bb0135","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s10787-018-0471-3","article-title":"Quinazoline clubbed 1,3,5-triazine derivatives as VEGFR2 kinase inhibitors: design, synthesis, docking, in vitro cytotoxicity and in ovo antiangiogenic activity","volume":"26","author":"Pathak","year":"2018","journal-title":"Inflammopharmacology"},{"issue":"17","key":"10.1016\/j.bioorg.2026.110333_bb0140","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1021\/acs.jmedchem.7b00930","article-title":"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K\/mTOR inhibitor as clinical candidate in oncology","volume":"60","author":"Beaufils","year":"2017","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110333_bb0145","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1021\/acsmedchemlett.9b00333","article-title":"Preclinical development of PQR514, a highly potent pi3k inhibitor bearing a difluoromethyl-pyrimidine moiety","volume":"10","author":"Borsari","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110333_bb0150","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jm901830p","article-title":"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5\u2032-triphosphate competitive phosphatidylinositol-3-kinase\/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor","volume":"53","author":"Venkatesan","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110333_bb0155","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jmgm.2015.10.005","article-title":"A structural insight into the inhibitory mechanism of an orally active PI3K\/mTOR dual inhibitor, PKI-179 using computational approaches","volume":"62","author":"Rehan","year":"2015","journal-title":"J. Mol. Graph. Model."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110333_bb0160","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.62347\/JCGQ1004","article-title":"A long-lasting PI3K\u03b4 inhibitor zandelisib forms a water-shielded hydrogen bond with p110\u03b4 and demonstrates sustained inhibitory effects","volume":"15","author":"Kunieda","year":"2025","journal-title":"Am. J. Cancer Res."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110333_bb0165","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1039\/D3SC04629J","article-title":"A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3K\u03b1","volume":"15","author":"Jauslin","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2026.110333_bb0170","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejmech.2018.03.066","article-title":"Phthalimide conjugations for the degradation of oncogenic PI3K","volume":"151","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110333_bb0175","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1016\/j.bmcl.2017.06.060","article-title":"Design and synthesis of 4-morpholino-6-(1,2,3,6-tetrahydropyridin-4-yl)-N-(3,4,5-trimethoxyphenyl)-1,3,5-triazin-2-amine analogues as tubulin polymerization inhibitors","volume":"27","author":"Narva","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110333_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113054","article-title":"Discovery of novel PARP\/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer","volume":"213","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110333_bb0185","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1016\/j.bmc.2018.10.014","article-title":"Design, synthesis and anti-melanogenic effect of cinnamamide derivatives","volume":"26","author":"Ullah","year":"2018","journal-title":"Bioorg. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:09:44Z","timestamp":1791407384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826008692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"alternative-id":["S0045206826008692"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110333","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel 1,3,5-triazine derivatives containing benzo[d]imidazole scaffold as PI3K inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110333"}}